Popular anti-obesity drugs continue to show cardiovascular benefits beyond weight loss, according to several new papers published in JACC that are being simultaneously presented at the American Heart ...

Popular anti-obesity drugs continue to show cardiovascular benefits beyond weight loss, according to several new papers published in JACC, the ...

A total of nearly 137 million adults, representing more than half of all U.S. adults, are eligible for semaglutide therapy. This ...

Ozempic is a medicine used to treat type 2 diabetes. It helps with weight loss by reducing appetite. Some foods have similar ...

Novo Nordisk (NVO) has reportedly launched its popular weight-loss drug Wegovy in China ahead of a rival drug by Eli Lilly ...

KOLs interviewed by GlobalData think that semaglutide can be a treatment option for non-diabetic CKD patients whose kidney ...

Findings suggest semaglutide and other GLP-1 agonists may significantly reduce alcohol use disorder hospitalizations, ...

Pharmacies that make customized medications are asking the federal Food and Drug Administration to protect their right to ...

Novo Nordisk and Eli Lilly are facing scores of personal injury claims for allegedly failing to warn patients about side ...

The popular weight loss drugs have also been found to reduce other risks, including the risk of death from COVID-19.

Ozempic, Wegovy and other GLP-1 drugs have been shown to curb alcoholism, a new study suggests. Researchers explain why ...

Today it is happening again with GLP1 agonists like Semaglutide with the brand names of Wegovy, Ozempic, and Rybelsus and similar drugs like Moujaro and Zepbound. And just like all the other weight ...